What the FDA labels say about taking them together
Temsirolimus and verapamil
Verapamil's FDA label of April 6, 2026 names temsirolimus in its drug interactions section; temsirolimus's label does not name verapamil itself but warns about its class (Calcium channel blockers). The verapamil label: “With concomitant use of mTOR inhibitors and verapamil, consider appropriate dose reductions of both medications.”
Check it at the source: the temsirolimus FDA label on DailyMed (effective December 26, 2025, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.); the verapamil FDA label on DailyMed (effective April 6, 2026, Zydus Pharmaceuticals (USA) Inc.).
What does the temsirolimus label say about verapamil?
Temsirolimus's label does not name verapamil itself; it warns about its class (Calcium channel blockers):
Temsirolimus label, drug interactionsIf alternative treatment cannot be administered, a dose adjustment should be considered [see Dosage and Administration (2.4) ]. Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine.
Temsirolimus label, drug interactionsMonitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).
Source: FDA drug label (Torisel), NDA022088 (Pf Prism Cv), as published by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective December 26, 2025 (SPL set 95b7dc92-2180-42f1-8699-3c28f609e674), via openFDA; the full label on DailyMed
What does the verapamil label say about temsirolimus?
Verapamil label, drug interactionsWith concomitant use of mTOR inhibitors (e.g., sirolimus, temsirolimus, and everolimus) and verapamil, consider appropriate dose reductions of both medications.
Source: FDA drug label (Verapamil hydrochloride), Zydus Pharmaceuticals (USA) Inc., effective April 6, 2026 (SPL set e19ab8d8-dae5-489d-9805-7e7407bea06d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Temsirolimus | Verapamil | |
|---|---|---|
| Labeled for | n/a | High blood pressure, Atrial fibrillation, Angina |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.191 per tablet 180 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once